Moderna, Inc. (MRNA) Q3 2020 Earnings Results

Moderna Misses on EPS, Stock Up 8.43%

Despite missing on EPS, Moderna's stock rose by 8.43%, likely driven by positive sentiment around their vaccine development efforts. Investors seem to be optimistic about the company's future potential, even in light of the earnings miss. The lack of revenue data and guidance may indicate uncertainty, but the focus on their pipeline remains a key point for investors.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.59	N/A	-38.50%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Management expressed confidence in their vaccine efforts and ongoing research. They acknowledged the challenges but remain focused on future developments.

Management highlighted ongoing progress in vaccine development.

They emphasized the importance of upcoming trials and partnerships.

The team remains focused on advancing their pipeline despite the EPS miss.

Moderna Misses on EPS, Stock Up 8.43%

Key numbers

Management commentary

Moderna, Inc.

More earnings this week

Moderna Misses on EPS, Stock Up 8.43%

Key numbers

Management commentary